Methods of promoting hepatic regeneration
The present invention relates to methods of accelerating, promoting or increasing hepatic regeneration, or increasing liver mass in a subject, by using a compound of formula (A): or a pharmaceutically acceptable salt thereof, and wherein R1, R2, R3, R4, R5, R6, m, and n are as described herein.
1. A method of accelerating, promoting or increasing hepatic regeneration in a subject with reduced liver function, comprising administering to the subject a therapeutically effective amount of a compound of formula (A):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen or C 1 -C 6 alkyl;
R 2 , R 3 , and R 5 are each independently hydrogen or hydroxyl;
R 6 is hydrogen;
R 4 is CO 2 H, C(O)NH(CH 2 ) m SO 3 H, C(O)NH(CH 2 ) n CO 2 H, or OSO 3 H; and
m and n are each independently 1, 2, or 3.
2. The method of claim 1 , wherein R 4 is CO 2 H or OSO 3 H.
3. The method of claim 1 , wherein R 1 is methyl, ethyl or propyl and R 5 is hydrogen.
4. The method of claim 1 , wherein R 2 is hydrogen and R 3 is hydroxyl.
5. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt.
8. The method of claim 6 , wherein the salt is a sodium or triethylammonium salt.
9. The method of claim 1 , wherein the subject has a transplanted liver.
10. The method of claim 1 , wherein the subject has a resected liver.
11. The method of claim 1 , wherein the reduced liver function is the result of surgical operation, disease, pathological condition, or injury.
12. The method of claim 11 , wherein the reduced liver function is the result of surgical operation.
13. The method of claim 12 , wherein the surgical operation is hepatic arterial embolization or portal venous manipulations.
14. The method of claim 12 , wherein the surgical operation is partial hepatectomy.
15. The method of claim 12 wherein the compound is administered prior to or after the surgical operation, or in combination.
16. The method of claim 11 , wherein the reduced liver function is the result of a disease or pathological condition selected from cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), drug induced cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition associated cholestasis (PNAC), bacterial overgrowth or sepsis associated cholestasis, autoimmune hepatitis, chronic viral hepatitis, alcoholic liver disease, liver transplant associated graft versus host disease, congenital hepatic fibrosis, choledocholithiasis, granulomatous liver disease, Sjogren's syndrome, sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis, and alpha 1-antitrypsin deficiency.
17. The method of claim 11 , wherein the reduced liver function is the result of a disease or condition is selected from hepatocellular carcinoma, intrahepatic malignancy and extrahepatic malignancy.
18. The method of claim 11 , wherein the reduced liver function is the result of an injury selected from drug-induced injury or physical injury.
19. A method of increasing liver mass in a subject with reduced liver function, comprising administering to the subject a therapeutically effective amount of a compound of formula (A):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen or C 1 -C 6 alkyl;
R 2 , R 3 , and R 5 are each independently hydrogen or hydroxyl;
R 6 is hydrogen;
R 4 is CO 2 H, C(O)NH(CH 2 ) m SO 3 H, C(O)NH(CH 2 ) n CO 2 H, or OSO 3 H; and
m and n are each independently 1, 2, or 3.